PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Condition:   Breast Neoplasms Interventions:   Drug: Palbociclib;   Drug: Placebo;   Drug: Tamoxifen;   Drug: Goserelin Sponsors:   National Cancer Center, Japan;   Pfizer;   Korean Cancer Study Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Pehlivan FS, Sivrikoz ON, Dag F, Kececi SD, Sanal SM Abstract We have investigated the distribution of chemokine receptor 4 (CXCR4) and CD8-positive, tumour-infiltrating T lymphocytes (CD8+ TILs) in breast cancer subtypes and explored the relationship between them and the well-established conventional prognostic markers, including axillary lymph node involvement. A total of 250 breast cancer patients were included in the study. The patients were separated into luminal A+B, HER2 enriched/overexpressed (HER2+), and triple- negative, on the basis of their staining characteristics, via conventional staining me...
Source: Polish Journal of Pathology - Category: Pathology Tags: Pol J Pathol Source Type: research
Authors: Barrios CH, Reinert T, Werutsky G Abstract Provision of high-level healthcare is a challenge for all low- to middle-income countries (LMICs) since healthcare systems are heterogeneous, face many challenges such as inadequate funding, inequitable distribution of resources and services and usually are not adequately equipped to deal with a huge problem such as breast cancer. The development of anti-HER2 therapies can be considered one of the most important examples of the translation of molecular biology knowledge into clinical benefits for cancer patients. While a variety of novel therapeutic strategies are...
Source: Ecancermedicalscience - Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research
Publication date: Available online 21 February 2019Source: Journal of the Taiwan Institute of Chemical EngineersAuthor(s): Chih-Hsiang Chang, I-Chi Tsai, Chung-Jen Chiang, Yun-Peng ChaoAbstractThe heterogeneous nature of cancers renders the efficacy of the therapeutic treatment diversified. To address this issue, a theranostic approach was proposed by development of a hybrid peptide for simultaneous diagnosis and therapy of cancer cells. Peptide A was composed of the biotinylation site (BS), the HER2/neu-binding motif, and the dockerin domain (Doc). Peptide B was designed with BS and the cohesin domain (Coh). Individually ...
Source: Journal of the Taiwan Institute of Chemical Engineers - Category: Chemistry Source Type: research
ConclusionsAIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative ILC.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
ConclusionsMammaPrint and BluePrint test results strongly impacted physicians ’ therapy decisions in luminal EBC with up to three involved lymph nodes. The high adherence to genetically determined risk assessment represents a key prerequisite for achieving a personalized cost-effective approach to disease management of early breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
AbstractPurposeWe evaluated whether multiplex protein quantification using antibody bar-coding with photocleavable oligonucleotides (NanoString) can be applied to evaluate protein expression in breast cancer FFPE specimens. We also assessed whether diagnostic core-cuts fixed immediately at time of procedures and surgical excision sections from routinely fixed breast cancers are affected by the same fixation related differences noted using immunohistochemistry (IHC).MethodsThe expression of 26 proteins was analysed using NanoString technology in 16 pairs of FFPE breast cancer core-cuts and surgical excisions. The measuremen...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Authors: Lambertini M, Viglietti G PMID: 30783509 [PubMed]
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
(Johns Hopkins Medicine) In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Condition:   HER2-positive Breast Cancer Intervention:   Drug: Pyrotinib+Trastuzumab+Docetaxel+Carboplatin Sponsor:   Shandong University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Breast Cancer;   Gastric/Gastroesophageal Junction Cancer Intervention:   Drug: KN026 Sponsor:   Jiangsu Alphamab Biopharmaceuticals Co., Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Hormones | Japan Health | Pfizer | Research | Study | Tamoxifen | Women